NASDAQ:FOLDAmicus Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $14.59 -0.64 (-4.20 %) (As of 08/11/2020 04:00 PM ET) Add Compare Share Today's Range$14.53Now: $14.59▼$15.7450-Day Range$14.45MA: $15.19▼$15.8952-Week Range$6.25Now: $14.59▼$16.13Volume2.70 million shsAverage Volume3.20 million shsMarket Capitalization$3.76 billionP/E RatioN/ADividend YieldN/ABeta1.28 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize Galafold as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingAmicus Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.28, Amicus Therapeutics has a potential upside of 39.0% from its current price of $14.59.Amount of Analyst CoverageAmicus Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform VotesAmicus Therapeutics has received 479 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAmicus Therapeutics has received 313 “underperform” votes. (Add your “underperform” vote.)Community SentimentAmicus Therapeutics has received 60.48% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote “Outperform” if you believe FOLD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FOLD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAmicus Therapeutics does not currently pay a dividend.Dividend GrowthAmicus Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amicus Therapeutics insiders have sold 31,312.14% more of their company's stock than they have bought. Specifically, they have bought $22,800.00 in company stock and sold $7,161,968.00 in company stock.Percentage Held by InsidersOnly 2.30% of the stock of Amicus Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Amicus Therapeutics are expected to grow in the coming year, from ($1.08) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amicus Therapeutics is -11.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amicus Therapeutics is -11.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmicus Therapeutics has a P/B Ratio of 7.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.60 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:FOLD Previous Symbol CUSIP03152W10 CIK1178879 Webwww.amicusrx.com Phone609-662-2000Debt Debt-to-Equity Ratio0.50 Current Ratio4.45 Quick Ratio4.31Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$182.24 million Price / Sales20.63 Cash FlowN/A Price / Cash FlowN/A Book Value$1.87 per share Price / Book7.80Profitability EPS (Most Recent Fiscal Year)($1.31) Net Income$-356,390,000.00 Net Margins-155.73% Return on Equity-63.24% Return on Assets-37.83%Miscellaneous Employees508 Outstanding Shares257,664,000Market Cap$3.76 billion Next Earnings Date11/9/2020 (Estimated) OptionableOptionable $14.59 -0.64 (-4.20 %) (As of 08/11/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive FOLD News and Ratings via Email Sign-up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions How has Amicus Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Amicus Therapeutics' stock was trading at $8.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FOLD stock has increased by 81.2% and is now trading at $14.59. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Amicus Therapeutics? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amicus Therapeutics. When is Amicus Therapeutics' next earnings date? Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020. View our earnings forecast for Amicus Therapeutics. How were Amicus Therapeutics' earnings last quarter? Amicus Therapeutics, Inc. (NASDAQ:FOLD) released its quarterly earnings data on Monday, August, 10th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.26) by $0.06. The biopharmaceutical company earned $62.35 million during the quarter, compared to analyst estimates of $62.66 million. Amicus Therapeutics had a negative net margin of 155.73% and a negative return on equity of 63.24%. View Amicus Therapeutics' earnings history. What guidance has Amicus Therapeutics issued on next quarter's earnings? Amicus Therapeutics updated its FY 2020 Pre-Market earnings guidance on Monday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $250-260 million, compared to the consensus revenue estimate of $254.82 million. What price target have analysts set for FOLD? 9 brokers have issued 12 month price targets for Amicus Therapeutics' shares. Their forecasts range from $12.50 to $31.00. On average, they expect Amicus Therapeutics' share price to reach $20.28 in the next twelve months. This suggests a possible upside of 39.0% from the stock's current price. View analysts' price targets for Amicus Therapeutics. Has Amicus Therapeutics been receiving favorable news coverage? Media headlines about FOLD stock have been trending negative on Wednesday, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amicus Therapeutics earned a news impact score of -2.6 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Amicus Therapeutics. Who are some of Amicus Therapeutics' key competitors? Some companies that are related to Amicus Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX). View all competitors. What other stocks do shareholders of Amicus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Sangamo Therapeutics (SGMO), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD) and Cara Therapeutics (CARA). Who are Amicus Therapeutics' key executives? Amicus Therapeutics' management team includes the following people: Mr. John F. Crowley, Chairman & CEO (Age 52)Mr. Bradley L. Campbell, Pres, COO & Director (Age 43)Ms. Ellen S. Rosenberg, Chief Legal Officer & Corp. Sec. (Age 56)Dr. Jay A. Barth, Chief Medical Officer (Age 55)Ms. Daphne E. Quimi, Chief Financial Officer (Age 53) What is Amicus Therapeutics' stock symbol? Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD." Who are Amicus Therapeutics' major shareholders? Amicus Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Jennison Associates LLC (1.97%), Victory Capital Management Inc. (1.36%), Assenagon Asset Management S.A. (0.61%), Fairmount Funds Management LLC (0.58%), Peregrine Capital Management LLC (0.38%) and Candriam Luxembourg S.C.A. (0.29%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc, Samantha Prout and William D Baird III. View institutional ownership trends for Amicus Therapeutics. Which institutional investors are selling Amicus Therapeutics stock? FOLD stock was sold by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd., Victory Capital Management Inc., Peregrine Capital Management LLC, Candriam Luxembourg S.C.A., GW&K Investment Management LLC, Asymmetry Capital Management L.P., Russell Investments Group Ltd., and Mackay Shields LLC. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Jay Barth, John F Crowley, Margaret G Mcglynn, Michael Raab, and Samantha Prout. View insider buying and selling activity for Amicus Therapeutics. Which institutional investors are buying Amicus Therapeutics stock? FOLD stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., SG Americas Securities LLC, Essex Investment Management Co. LLC, Fairmount Funds Management LLC, Swiss National Bank, DNB Asset Management AS, Rafferty Asset Management LLC, and Diversified Trust Co. Company insiders that have bought Amicus Therapeutics stock in the last two years include Burke W Whitman, Life Sciences Maste Perceptive, and Perceptive Advisors Llc. View insider buying and selling activity for Amicus Therapeutics. How do I buy shares of Amicus Therapeutics? Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Amicus Therapeutics' stock price today? One share of FOLD stock can currently be purchased for approximately $14.59. How big of a company is Amicus Therapeutics? Amicus Therapeutics has a market capitalization of $3.76 billion and generates $182.24 million in revenue each year. The biopharmaceutical company earns $-356,390,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Amicus Therapeutics employs 508 workers across the globe. What is Amicus Therapeutics' official website? The official website for Amicus Therapeutics is www.amicusrx.com. How can I contact Amicus Therapeutics? Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected] This page was last updated on 8/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
